Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2-CAR-T in HER2+ solid tumors
NCT06101082Phase 1Recruiting
- Sponsor
- China Medical University
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-HER2 CAR-T cells in solid tumor, sponsored by China Medical University. Primary endpoint: Dose-limiting toxicity at 21 days. Started Jan 2024; status: recruiting.
02
Drugs
anti-HER2 CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06101082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101082.